Endocrine Abstracts

Pregnancy is associated with an increased risk of tumor growth in macroprolactinoma leading to discuss surgery in such cases.Objectives: Impact of pregnancy on prolactin secretion and tumor growth in a cohort of women with macroprolactinoma, including large tumors >20 mm, and medically treated.Methods: Retrospective study of all the women with macroprolactinomas diagnosed in two university hospitals, treated by dopamine agonist...

Objectives: Long-term results of medical treatment of macroprolactinoma in children and adolescents (<20 years).Patients and methods: Retrospective analysis of all the cases of macroprolactinoma occurring in children and adolescents, medically treated in two university centers.Results: 38 patients, 25 girls 13 boys, age at diagnosis: 15.7±2.8 years (only two cases before 12 years). At diagnosis, 2/3 presented with headache...

Lost to follow-up (LTFU) is a frequent problem in chronic diseases not evaluated yet in acromegaly despite the long-term need of medical treatment and complications survey in this disease.Objectives: Evaluation of the prevalence of LTFU patients in a multi-center cohort, characteristics of defaulters and description of their evolution after they have been searched and found.Méthods: Observational multicentric (25 centers study...

Study aim: Pituitary function evaluation in patients with traumatic brain injury (TBI).Subjects: One hundred and forty-six patients (49 female, 97 men, age: 31.9±16.2 years) recovered from moderate to severe TBI. Prospective follow up has been performed 3/6 and 12 months from TBI for 79 subjects. Retrospective evaluation (from 0.3 to 30 years) included 67 subjects selected in front of overt clinical features (obesity, fatigue, sexual disorders)....

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drug’s efficacy and safety in patients with Cushing’s disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushing’s syndrome (CS) in adults....